問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2014-03-19 - 2016-12-31
Condition/Disease
Test Drug
Participate Sites3Sites
Terminated3Sites
2014-03-01 - 2017-12-31
Participate Sites13Sites
Terminated13Sites
2014-11-01 - 2020-12-31
Moderate to Severe Plaque-type Psoriasis
CNTO1959(guselkumab)
Participate Sites5Sites
Terminated5Sites
2010-01-08 - 2011-07-31
Participate Sites9Sites
Terminated9Sites
2006-08-01 - 2008-05-31
Participate Sites4Sites
Terminated4Sites
2006-10-01 - 2010-06-30
2015-07-01 - 2020-12-31
Participate Sites7Sites
Terminated7Sites
Division of Thoracic Medicine
2015-07-01 - 2019-03-31
Advanced Solid Tumours
MEDI4736
Not yet recruiting3Sites
Division of Hematology & Oncology
2015-10-22 - 2019-12-31
Squamous Cell Head and Neck Cancer
MEDI4736; Tremelimumab
Participate Sites8Sites
未分科
Division of Otolaryngology
2014-02-01 - 2016-01-31
Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset
Ticagrelor
Participate Sites11Sites
Terminated10Sites
Study ended1Sites
Division of Neurology
全部
